Skip to main content. Skip to left menu.
  Change Text Size -+
Learn more about AvaproLearn more about Avalide
Tools for Your Patients
Print out and share with your patients a Personal Blood Pressure Tracker, patient brochure, and a Healthy Meal Planner. Read descriptions and print out these materials for use with your appropriate hypertensive patients now
Indications
AVAPRO is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

AVAPRO is also indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. In this population, AVAPRO reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation).

AVALIDE is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy.

Important Safety Information

USE IN PREGNANCY: When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, AVAPRO or AVALIDE should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.
  • Because of the hydrochlorothiazide component, AVALIDE is contraindicated in patients with anuria or hypersensitivity to sulfonamide-derived drugs
  • In patients with volume or sodium depletion (eg, patients vigorously treated with diuretics or on dialysis), such depletion should be corrected prior to administration of AVAPRO or AVALIDE, or a lower initial dose of AVAPRO (75 mg) should be used, to avoid possible symptomatic hypotension
  • In placebo-controlled hypertension studies, there were no significant differences in adverse events (AEs) between AVAPRO and placebo. Adverse events that occurred in at least 1% of patients treated with AVAPRO and at a higher incidence vs placebo included diarrhea (3% vs 2%), dyspepsia/heartburn (2% vs 1%), and fatigue (4% vs 3%)
  • Additionally, in a study of hypertensive type 2 diabetic patients with renal disease (proteinuria > 900 mg/day), the reported AEs for AVAPRO were similar to those seen in hypertension studies, with the exception of an increased incidence of orthostatic symptoms; AVAPRO compared to placebo (both groups received adjunctive antihypertensives): dizziness (10.2% vs 6.0%); orthostatic dizziness (5.4% vs 2.7%); and orthostatic hypotension (5.4% vs 3.2%), respectively. In patients with proteinuria, monitor serum potassium
  • Most common adverse experiences reported in AVALIDE-vs-placebo clinical trials: fatigue (7% vs 3%); musculoskeletal pain (7% vs 5%); dizziness (8% vs 4%); and nausea/vomiting (3% vs 0%)
  • Thiazides should be used with caution in patients with severe renal disease and in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma
  • Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history
  • Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus
  • Lithium generally should not be given with thiazides
Please see full Prescribing Information.


 

Bristol-Myers Squibb Sanofi-Synthelabo Partnership
© 2007 Bristol-Myers Squibb Sanofi-Synthelabo Partnership 446US07WA27501 10/07 Last updated: October 2007